Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Update

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a drop of 21.3% from the November 30th total of 1,500,000 shares. Currently, 4.5% of the company’s stock are sold short. Based on an average daily trading volume, of 16,290,000 shares, the short-interest ratio is currently 0.1 days.

Insider Buying and Selling at Tevogen Bio

In other news, insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the sale, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. The trade was a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 56.60% of the company’s stock.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. bought a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned about 0.13% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Stock Up 1.9 %

Shares of TVGN stock traded up $0.02 on Monday, hitting $1.05. 1,035,036 shares of the stock were exchanged, compared to its average volume of 4,657,006. Tevogen Bio has a one year low of $0.26 and a one year high of $21.09. The firm’s 50 day moving average is $1.49 and its two-hundred day moving average is $0.93.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.